1
EXHIBIT 11
STATEMENT RE COMPUTATION OF PER SHARE EARNINGS
The computation of net income (loss) per share for the years ended
December 31, 1993, 1992 and 1991 is as follows:
1993 1992 1991
---- ---- ----
Primary
Net income (loss)........................................ $(11,270,000) $(64,802,000) $ 5,855,000
Dilution in earnings which would
result upon the exercise of
options and warrants currently
outstanding to purchase common
shares of subsidiaries................................. -- (603,000) (745,000)
----------- ----------- -----------
$(11,270,000) $(65,405,000) $ 5,110,000
=========== =========== ===========
Average common shares outstanding........................ 19,813,000 14,010,000 11,776,000
Dilutive common equivalent shares
issuable upon the exercise of
options and warrants currently
outstanding to purchase common
shares of ICN Pharmaceuticals,
Inc.................................................... -- -- 1,053,000
----------- ---------- -----------
19,813,000 14,010,000 12,829,000
=========== ========== ===========
Net income (loss) per share.............................. $ (.57)$ (4.67) $ .40
=========== ========== ===========
FULLY DILUTED
Net income............................................... (1) (1) 5,855,000
Dilution in earnings which would
result upon the exercise of
options and warrants currently
outstanding to purchase common
shares................................................. (745,000)
Conversion of debentures................................. 4,835,000
-----------
9,945,000
-----------
Average common shares outstanding 11,766,000
Dilutive common equivalent shares
issuable upon the exercise of
options and warrants currently
outstanding to purchase common
shares of ICN Pharmaceuticals, Inc..................... 1,539,000
Conversion of debentures................................. 3,671,000
-----------
16,986,000
-----------
Net income (loss) per share $ .58
===========
(1) Not applicable.
120